Rather than trying to propose an abstract definition of ADEV, the problem can be by-passed by compiling a list of operational units that would be considered as being under the broad ADEV umbrella. This has been done in Appendix III. However, output statistics, such as counts of lead structures from such units, individually or collectively, are difficult to find. This is not an access problem in terms of primary disclosures (i.e. their papers, patents, press releases and clinical trials results surface alongside those of the commercial sector) but the difficulty lies more on the indexing side. Much of this stems from the pragmatic aspect that commercial organisations, from the largest pharma company down to the smallest biotech, will self-assign specific names (even 'Google clean' where possible). Consequently, they can become identifiable as registered business units, patent assignees, affiliations on journal papers, press releases, indexed in Google and, last but not least, for shareholder information.